Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Defense Logistics Agency is seeking proposals for the supply of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets, under solicitation SPE2DP-25-R-0001, expected to be issued around August 2025. The contract will be firm-fixed price with a base year and four option years, requiring FDA approval for bidders. Delivery will be monthly to military recruiting activities across the U.S., starting three months post-award. Interested parties should register on the DLA DIBBS website for updates.
Solicitation: SPE2DP-25-R-0001 Item: Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration (Adeno) NSN: 6505-01-642-0106 Description(s): The Defense Logistics Agency Troop Support has a requirement for the supply of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration (Adeno). NSN 6505-01-642-0106. The vaccine shall be enteric-coated tablets of live, adenovirus Type 4 and Type 7 suitable for oral administration only. One Package (PG) consists of Two (2) bottles of 100 tablets each of Type 4 and 100 tablets each of Type 7 Adenovirus Vaccine, Live, Oral. Other specification data will be included in the solicitation. The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1). The Government does not intend to use Part 12 for this acquisition per FAR 10.002(d)(2). The successful contractor shall have FDA approval to supply Adeno before award decision. The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of one (1) base year and four (4) one-year options. The estimated annual quantity for the base year and each option year is 2,000 PG. There will be a minimum quantity of 1,500 PG and a maximum quantity of 2,300 PG for the base year and each option year. (Quantities may increase or decrease pending receipt of final Service requirements.) FOB Destination. Ordered quantities shall be delivered to military recruiting activities located throughout the United States. Delivery is scheduled on a monthly basis. First deliveries shall begin 3 months after award of contract, or best available delivery, negotiated between the contractor and the Government. All responsible sources may submit a proposal, which, if timely received, shall be considered by the Agency. **************************************************************************** IMPORTANT NOTICES Availability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-25-R-0001 is expected to be issued on or around August 2025.
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.